Endocyte (ECYT) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
- Oil prices fall to seven-week low as Iran and Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Supermicro plans $7 billion financing to fund AI server orders
Endocyte Reports Third Quarter 2016 Financial Results
November 9, 2016 4:01 PM EST- Confirmed Maximum Dose for EC1169 and Initiated Expansion Phase in Prostate Cancer Patients -
- First Confirmed RECIST Partial Response Observed in EC1169 Dose Escalation Reported at European Society for Medical Oncology (ESMO) in October
- Conference Call Today at 4:30 p.m. EST -
WEST LAFAYETTE, Ind., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Â Endocyte, Inc. (NASDAQ: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized... More
